Molnar-Institute - Pharma Technology Focus | Issue 96 | July 2020

DryLab's Empower-Automated AQbD Modeling Workflow

Empower Automated

www.DryLab.com

06/26/2020 09:07:45

Home | Breaking the Barrier
In this issue
NSF
Contents
Almac
News
VEGA Company Insight
VEGA Australia
Covid-19 executive briefing by GlobalData
Gilead’s remdesivir a candidate for US government stockpiling or bulk buying in
Covid-19’s impact on trial PROs, other endpoints can be addressed via data stratification, sensitivity analysis
ILC Dover
Vitamin D affects Covid-19 mortality
Clinical trial disruption due to Covid-19 has begun to slow
Covid-19 boosts big bio/pharma drug sales but Regeneron may be falling short
Mimotopes
The pharma industry briefing
Charting the ups and downs of the World Health Organization
Road to RECOVERY: a deep dive into the world’s largest Covid-19 drug trial
Salvaging clinical trials in the time of Covid-19
Intellectual property in the time of Covid-19
Molnár-Institute Company Insight
Molnar-Institute
A plight for sore eyes: the latest developments in seasonal allergy treatment
How research groups are tackling the problem of biologic drug delivery
Breaking the blood-brain barrier: neurology’s greatest challenge
Timeline: charting the history of immunotherapy, cancer treatment's fourth pillar
Creating a sure data footing for AI
Koehler eClinical
Deals in brief powered by GlobalData
The key list powered by GlobalData
Global markets and indices powered by GlobalData
Macro-economic indicators (1 of 2) powered by GlobalData
Macro-economic indicators (2 of 2) powered by GlobalData
Events
Next issue